Abstract
Purpose. To compare the venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats after intravenous administration of a submicron lipid emulsion with that of an aqueous solution.
Methods. Venous irritation was determined by microscopic evaluation of injury to the lateral tail veins of rats. Pharmacokinetic parameters were determined by following plasma concentrations of drug. Tissue distribution of [14C]-tirilazad was determined by quantitative whole body autoradiography.
Results. Single dose injections of tirilazad as an emulsion at doses ranging from 1.52 mg to 13.5 mg were non-irritating whereas the solution was irritating at a dose of 1.3 mg. The pharmacokinetic parameters were not statistically different between the emulsion and the solution (p > 0.2) at doses of 6 mg/kg/day and 20 mg/kg/day. However, at 65 mg/kg/day dose, a higher AUC(0,6) (4-fold) and lower Vss (18-fold) and CL(5-fold) were observed for the lipid emulsion as compared to the solution (p < 0.05). Tissue distribution showed higher initial concentrations (two fold or more) in most tissues for the solution. These values, however, equilibrated by 4 h and AUC(0,4) differences were less than two fold in most tissues.
Conclusions. Formulating tirilazad in the lipid emulsion significantly reduces the venous irritation without changing the pharmacokinetics and tissue distribution at low doses.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
J. M. Braughler, P. S. Burton, R. L. Chase, J. G. Pregenzer, E. J. Jacobsen, F. J. VanDoornik, J. M. Tustin, D. E. Ayer, and G. L. Bundy. Novel membrane localized inhibitors of iron-dependent lipid peroxidation. Biochem. Pharmacol. 37:3853–3860 (1988).
J. M. Braughler, E. D. Hall, E. J. Jacobsen, J. M. McCall, and E. D. Means. The 21-aminosteroids: Potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drugs Future 14:143–152 (1989).
J. C. Fleishaker, G. R. Peters, and K. S. Cathcart. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration. J. Clin. Pharmacol. 33:175–181 (1993).
J. C. Fleishaker, G. R. Peters, K. S. Cathcart, and R. C. Steenwyk. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Multiple-dose administration. J. Clin. Pharmacol. 33:182–190 (1993).
S. S. Davis, C. Washington, P. West, L. Illum, G. Liversidge, L. Sternson, and R. Kirsh. Lipid emulsions as drug delivery systems. Ann. N. Y. Acad. Sci. 507:75–88 (1987).
A. M. Thorn-Alquist. Parenteral use of diazepam in an emulsion formulation. A clinical study. Acta Anaesth. Scand. 21:400–404 (1977).
P. Westrin, C. Jonmarker, and O. Werner. Dissolving methohexital in a lipid emulsion reduces pain associated with intravenous injection. Anaesthesiology 76:930–934 (1992).
M. W. Lovell, H. W. Johnson, H.-W. Hui, J. B. Cannon, P. K. Gupta, and C. C. Hsu. Less-painful emulsion formulations for intravenous administration of clarithromycin. Int. J. Pharm. 109:45–57 (1994).
H. Stuttmann, A. Doenicke, J. Kugler, and M. Laub. A new formulation of etomidate in lipid emulsion. Bioavailability and venous irritation. Anaesthesist. 38:421–423 (1989).
J. B. Glen and S. C. Hunter. Pharmacology of an emulsion formulation of IC1 35868. Br. J. Anaesth. 56:617–625 (1984).
Y. Wang and A. L. Cory. A novel stable supersaturated submicron lipid emulsion of tirilazad. Pharma. Dev. Tech. In press.
RSTRIP-Exponential stripping and parameter estimation, v 5.0, Micromath Scientific Software, Salt Lake City, UT.
M. Gibaldi and D. Perrier. Pharmacokinetics. 2nd Ed. New York, NY. Marcel Dekker, 1982.
SAS Institute, Inc. Cary, N. C.
D. G. Kleinbaum, L. Kupper, and K. E. Muller. Applied regression analysis and other multivariable methods. Boston, MA. PWS KENT Publishing Co. 1988.
D. Sandeep and W. F. Ebling. Formulation-dependent pharmaco-kinetics and pharmacodynamics of propofol in rats. J. Pharm. Pharmacol. 50:37–42 (1998).
A. Kurihara, Y. Shibayama, A. Mizota, A. Yasuno, M. Ikeda, and M. Hisaoka. Pharmacokinetics of highly lipophilic antitumor agent palmitoyl rhizoxin incorporated in lipid emulsions in rats. Biol. Pharm. Bull. 19:252–258 (1996).
Y. Kato, K. Watanabe, M. Nakakura, and T. Hosokawa. Blood clearance and tissue distribution of various formulations of α-tocopherol injection after intravenous administration. Chem. Pharm. Bull. 41:599–604 (1993).
J. W. Cox, G. P. Sage, M. A. Wynalda, R. G. Ulrich, P. G. Larson, and C. C. Su. Plasma compability of injectables: Comparison of intravenous U-74006, a 21-aminosteroid antioxidant, with Dilantin brand of parenteral phenytoin. J. Pharm. Sci. 80(4):371–375 (1991).
L. Illum. The targeting of drugs parenterally by use of microspheres. J. Parenteral Sci. Technol. 36(6):242–248(1982).
J. W. Cox, P. G. Larson, M. A. Wynalda, V. K. Sood, M. T. Verburg, and R. N. Pullen. Pharmacokinetics and excretion of the 21-aminosteroid antioxidant U-74006F in rat and perfused rat liver. Drug Metab. Dispos. 17:373–379 (1989).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, Y., Mesfin, GM., Rodríguez, C.A. et al. Venous Irritation, Pharmacokinetics, and Tissue Distribution of Tirilazad in Rats Following Intravenous Administration of a Novel Supersaturated Submicron Lipid Emulsion. Pharm Res 16, 930–938 (1999). https://doi.org/10.1023/A:1018846607804
Issue Date:
DOI: https://doi.org/10.1023/A:1018846607804